Oncology News

Patients with hepatitis B had a higher risk for hepatocellular carcinoma after HBV e antigen seroclearance if they were men, had higher levels of HBV DNA, were unable to achieve normalized alanine aminotransferase levels, and were older at the time of HBeAg seroclearance, according to a recently published study.

Recently published data showed no association between direct-acting antiviral therapy and an increased risk for hepatocellular carcinoma recurrence among liver transplantation candidates with hepatitis C who experienced initial complete response to local-regional therapy.

Higher concentration of vitamin D correlated significantly with a lower risk for overall cancer and liver cancer, according to recently published data.

Baseline hepatitis B DNA and end-of-treatment HBV surface antigen levels predicted virological relapse among patients with chronic HBV who ceased Baraclude or Viread therapy during chemotherapy, according to a recently published study.

Boston Scientific announced that it has acquired EMcision, a company based in the United Kingdom and Canada.

Myosteatosis, low BMI and low alanine aminotransferase levels correlate with skeletal volume loss in patients with chronic liver disease, especially among women, according to recently published data.

The high efficacy of direct-acting antivirals correlated with significant improvement in survival of patients who underwent liver transplantation for hepatitis C-related liver disease, according to a recently published study.

Specialized chronic disease management for patients with chronic liver disease demonstrated high potential to be more cost-effective than standard care due to fewer patient deaths, according to recently published data.

Magnetic resonance imaging alone to detect early-stage hepatocellular carcinoma had a low level of sensitivity among patients with cirrhosis, according to a recently published meta-analysis. However, ultrasound with alpha-fetoprotein significantly increased the sensitivity of HCC detection.

Patients treated with long-term combined entecavir and tenofovir for chronic hepatitis B had overall and liver-related 8-year survival rates similar to the general population, except for those with hepatocellular carcinoma, according to recently published data.